Teva launches Herceptin biosimilar in U.S.

Teva Pharmaceutical Industries (TEVA -11.1%) announces the availability of Herzuma (trastuzumab-pkrb), a biosimilar to Roche’s (OTCQX:RHHBY -4%) Herceptin, in the U.S.

The Wholesale Acquisition Cost (WAC) is $1,402.50 for the 150 mg product and $3,927.00 for 420 mg, a 10% discount to the WAC of Herceptin.

For comparison purposes, Pfizer launched its Herceptin biosimilar, Trazimera, on February 19 at a 22% discount to the original while Amgen (AMGN -1.5%) and collaboration partner Allergan (AGN -7.9%) launched Kanjinti, their Herceptin biosimilar, in July 2019 at a 15% discount.

https://seekingalpha.com/news/3552122-teva-launches-herceptin-biosimilar-in-u-s